Contineum Therapeutics (CTNM) reported late Monday dosing of the first cohort of patients in the PIPE-791 phase 1b positron emission tomography trial.
The study is expected to measure the correlation of pharmacokinetics to receptor occupancy by positron emission tomography imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis and progressive multiple sclerosis patients, it said.
Contineum said it expects topline data from the trial in Q2 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。